title: A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of oxaliplatin and paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  The treatment regimen was given as defined in a phase I investigation in patients with previously treated ovarian cancer. It consisted of paclitaxel 175 mg/m(2) (1-h infusion) and oxaliplatin 130 mg/m(2) (2-h infusion) given every 21 days. Eligible patients had stage IIIB (pleural effusion)/IV NSCLC, measurable disease, no prior chemotherapy, Eastern Cooperative Oncology Group performance status 0-2, and adequate hematological, renal and hepatic function.
  
  
  RESULTS
  A total of 38 patients were enrolled with the following characteristics: 29% male (n = 11); 71% female (n = 27); median age 64.5 years (range 37-78); performance status of 0-1 84% (n = 32); stage IIIB 8% (n = 3); stage IV 92% (n = 35). One hundred and eighty-one cycles were administered, with a median of four per patient (range one to 12). The overall objective response rate for all 38 patients was 34.2% [95% confidence interval (CI) 19.6% to 51.4%]. This response rate includes 13 patients who met criteria for a partial response. No complete responses were observed. Median overall survival time was 9.2 months (95% CI 6-12.4) and median progression-free survival time was 4.3 months (95% CI 2.1-6.5). The 1- and 2-year overall survival rates were 37% and 21%, respectively. Hematological toxicity included six patients with grade 4 neutropenia. Non-hematological toxicity consisted mainly of grades 1 and 2 neurosensory toxicity. Laryngodysesthesia was observed in two patients following oxaliplatin infusion. No grade 4 non-hematological toxicities were encountered.
  
  
  CONCLUSIONS
  This regimen is well tolerated, and demonstrates activity in patients with advanced NSCLC.
authors.affiliation: University of Chicago Section of Hematology/Oncology and University of Chicago Cancer Research Center, Chicago, IL 60637, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Winegarden
authors.forename: A M
authors.initials: AM
authors.lastname: Mauer
authors.forename: G A
authors.initials: GA
authors.lastname: Otterson
authors.forename: C M
authors.initials: CM
authors.lastname: Rudin
authors.forename: M A
authors.initials: MA
authors.lastname: Villalona-Calero
authors.forename: V J
authors.initials: VJ
authors.lastname: Lanzotti
authors.forename: L
authors.initials: L
authors.lastname: Szeto
authors.forename: K
authors.initials: K
authors.lastname: Kasza
authors.forename: P C
authors.initials: PC
authors.lastname: Hoffman
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D017239:Paclitaxel